Home
News
Topics
Sectors
Reports
Events
Clusters
Products
WEEKLY
FOCUS
ALPHA
Search
About Us
Sign in
Chemical Industry News, Data & Insights
About Us
Sign in
Home
News
Topics
Sectors
Reports
Events
Clusters
Products
WEEKLY
FOCUS
ALPHA
Products
WEEKLY
FOCUS
ALPHA
Semaglutide news
(page 2)
All news on
Semaglutide
(also known as
Wegovy
and
Ozempic
): plants, production capacities, investments and involved companies.
31 December 2025
Novo Nordisk Wins Semaglutide Patent Case in China
China's Supreme Court upholds the semaglutide patent, boosting confidence in foreign medical innovation and supporting sustainable development in China.
22 December 2025
FDA Approves Novo Nordisk's Oral Wegovy for Adult Weight Loss
FDA approves Wegovy pill, the first oral GLP-1 for weight loss, showing ~17% loss in trials. Available January at $149/month, it also reduces cardiovascular risks in adults with obesity.
22 December 2025
Novo Nordisk: FDA Approves Wegovy® Oral Pill for Weight Management
Wegovy® pill, an oral GLP-1, shows 16.6% weight loss in trials. Launch expected in the US by January 2026. Approval based on OASIS and SELECT trials.
18 December 2025
Lilly's Orforglipron Maintains Weight Loss in Phase 3 Trial
Orforglipron met primary and key secondary endpoints for weight maintenance at 52 weeks post-weight loss on Wegovy. FDA submission for obesity treatment is underway.
18 December 2025
Novo Nordisk Seeks FDA Approval for CagriSema, a Weekly Obesity Treatment
CagriSema, combining cagrilintide and semaglutide, shows 23% weight loss in trials. If approved, it offers a new obesity treatment option.
18 December 2025
Novo Nordisk Seeks FDA Approval for CagriSema, a Weekly Obesity Treatment
CagriSema, a weekly injectable combining GLP-1 and amylin analogues, shows promising weight loss results in trials and awaits FDA review for obesity management.
Who will be producing Semaglutide in the future?
Find out with
chemXplore Alpha
Learn more
12 December 2025
Novo Nordisk: EMA Recommends Higher Wegovy® Dose for 20.7% Weight Loss
EMA backs Wegovy® 7.2 mg for obesity, showing 20.7% weight loss in trials, preserving muscle, and reducing cardiovascular risks. Approval pending in EU, US, UK, and more.
26 November 2025
Novo Nordisk Seeks FDA Approval for Higher Dose of Wegovy 7.2 mg
FDA to review semaglutide 7.2 mg for obesity under expedited program. Phase 3 trial shows 20.7% weight loss. Approval offers new weight management option.
24 November 2025
Novo Nordisk: Phase 3 Trials Show No Significant Impact on Alzheimer's Progression
Semaglutide showed no significant effect on Alzheimer's progression in phase 3 trials, despite improving biomarkers. Trials will not continue due to lack of efficacy.
10 November 2025
Novo Nordisk: Wegovy® Shows Liver Health Benefits Beyond Weight Loss in MASH Patients
Semaglutide 2.4 mg improves liver health in MASH patients, showing benefits across weight loss levels and diverse demographics, according to ESSENCE trial data.
6 November 2025
Novo Nordisk's CagriSema Reduces Blood Pressure and Inflammation, Lowers Heart Disease Risk
CagriSema shows potential in reducing blood pressure, inflammation, and heart disease risk, with ongoing trials to assess cardiovascular outcomes.
6 November 2025
Novo Nordisk and U.S. Administration to Lower GLP-1 Costs and Expand Access
Novo Nordisk to lower semaglutide prices in 2026, expand Medicare Part D coverage, and expects a slight negative impact on global sales growth.
5 November 2025
Novo Nordisk's Wegovy® Helps Users Meet Health Targets, Reducing Obesity Risks
Wegovy® users achieved BMI and waist targets, improving cardiovascular health and reducing obesity-related risks, as shown in the STEP UP trial.
5 November 2025
Novo Nordisk Reports 12% Sales Growth in DKK, 15% at CER, and R&D Advances in First Nine Months of 2025
Operating profit rose 5% in DKK, 10% at CER. Obesity care sales up 37%. FDA approved Wegovy® for MASH. Novo Nordisk to acquire Akero Therapeutics. Full-year sales growth forecast at 8-11% CER.
5 November 2025
Novo Nordisk Unveils New Oral Semaglutide Analyses at ObesityWeek 2025
Oral semaglutide 25 mg shows improved blood sugar control, cardiovascular risk factors, and weight loss efficacy, comparable to injectable form, across various patient groups.
28 October 2025
Novo Nordisk to Present Wegovy® Data at 2025 AASLD Meeting
11 abstracts on Wegovy® and MASH to be presented at AASLD 2025, highlighting clinical and real-world data, including post-hoc analyses of the ESSENCE trial.
20 October 2025
Novo Nordisk to Present Oral Semaglutide and Obesity Data at ObesityWeek 2025
New data on oral semaglutide and CagriSema will be presented, focusing on weight loss efficacy, cardiometabolic health, and women's health in obesity management.
17 October 2025
FDA Approves Novo Nordisk's Oral Semaglutide for CV Risk Reduction in High-Risk Type 2 Diabetes Adults
Oral semaglutide reduces major cardiovascular events in high-risk type 2 diabetes patients, showing a 14% risk reduction over 4 years, with consistent safety profile.
9 October 2025
Novo Nordisk Acquires Akero Therapeutics to Enhance MASH Treatment Portfolio
Novo Nordisk acquires Akero for $4.7B, adding efruxifermin, a promising MASH treatment, to its portfolio. The deal includes a $0.5B contingent value right upon regulatory approval.
18 September 2025
Novo Nordisk: Ozempic® Cuts Heart Attack, Stroke, and Death Risk by 23% vs. Dulaglutide
Ozempic® shows 26% lower death risk and 25% reduced risk of major cardiovascular events in older diabetes patients compared to dulaglutide in a real-world study.
17 September 2025
Novo Nordisk's Oral Semaglutide Achieves 16.6% Weight Loss in Obesity Study
Oral semaglutide 25 mg shows significant weight loss and improved physical activity in a 64-week trial, with mild to moderate side effects, pending FDA approval.
16 September 2025
Novo Nordisk Advances Cagrilintide to Phase 3 Clinical Program After Positive Results
Cagrilintide shows significant weight loss and tolerability in trials, prompting further study in the RENEW phase 3 program for obesity treatment.
15 September 2025
Novo Nordisk's Wegovy® Reduces Food Noise, Enhances Mental Well-being
Wegovy® users reported a 46% drop in constant food thoughts, improved mental health (64%), and healthier habits (80%) in a real-world survey.
15 September 2025
Novo Nordisk's Oral Semaglutide Approved in EU for Cardiovascular Benefits
EMA approves Rybelsus® label update for cardiovascular benefits in type 2 diabetes. SOUL trial shows reduced hospitalizations and consistent benefits across BMI and weight.
5 September 2025
Novo Nordisk to Present Semaglutide and Pipeline Data at EASD Congress
Novo Nordisk to present data on semaglutide's effects on food noise, body composition, and cardiovascular benefits, plus new obesity treatments at EASD 2025.
31 August 2025
Novo Nordisk: Wegovy® Reduces Heart Attack, Stroke, Death Risk by 57% vs. Tirzepatide
Wegovy® shows 57% greater risk reduction in heart events vs. tirzepatide in obese patients with CVD. Benefits are specific to semaglutide, not general to GLP-1 or GIP/GLP-1 classes.
6 May 2013
Novo Nordisk Invests DKK 380 Million in Kalundborg Plant
The investment will create 50 jobs and convert existing facilities for semaglutide production, a new type 2 diabetes treatment. The plant will be operational by Q1 2014.
← Previous
